About Us

In this Section

2011 News Archive

Sept 26, 2011

Budapest, Hungary, and Zug, Switzerland (September 26, 2011) – ImmunoGenes AG announced today that the company has been selected to present at the PolyTechnos Life Science Entrepreneurial Day which will be held in New York City on October 25, 2011 (web). This event, which is designed to provide insight into some of the major changes affecting investment in the healthcare sector along with an opportunity to network with key players, will highlight several companies in the PolyTechnos network.

Imre Kacskovics, the company’s CEO and scientific founder, will present an overview of the Company's business strategy and details on several new findings from its proprietary platform technology to improve antibody generation and production using FcRn-overexpressing animals. The company is also available for one-on-one meetings while it is in New York by contacting Lee Schalop at schalop@immunogenes.com.

“We are very pleased to have ImmunoGenes as part of our PolyTechnos Life Science Entrepreneurial Day” said Wolfgang Oster, managing partner of PolyTechnos. “Our goal at this conference is to demonstrate how PolyTechnos adds value and creates competitive investment opportunities, and the significant success of ImmunoGenes in transforming from an academic idea into a commercially successful enterprise with signed agreements with some of the largest names in biotech and pharma is an excellent example of this capability.”

Back to Top

Sept 13, 2011

Budapest, Hungary, and Zug, Switzerland (September 13, 2011) – ImmunoGenes AG announced today that the company has been selected to present on the Discovery Track at the 10th Annual Bio Investor Forum on Wednesday, October 26, 2011, at 9:45 a.m. at The Palace Hotel in San Francisco (web). ImmunoGenes is honored to have been chosen to take part in the BIO Investor Forum, which is designed to “explore investment trends and opportunities in life sciences, with a focus on public and venture-stage growth companies as well as those poised to join the growth ‘watch list’ in 2012.”

Lee Schalop, the company’s Chief Operating Advisor and Head of Business Development, will present an overview of the Company's business strategy and details on several new findings from its proprietary platform technology to improve antibody generation and production using FcRn-overexpressing animals. The company is also available for one-on-one meetings at the Bio Investor Forum by contacting Lee Schalop at schalop@immunogenes.com.

“We are particularly excited to be presenting at this year’s Bio Investor Forum,” said Imre Kacskovics, the CEO of ImmunoGenes. “Our company’s proprietary technology that allows for an improved immune response will lead to important advances in critical drugs and diagnostics, which we believe fits perfectly with the mission of the Bio Investor Forum to identify news trends in the life sciences.”

Back to Top

Aug 11, 2011

Budapest, Hungary, and Zug, Switzerland (August 11, 2011) – ImmunoGenes AG announced today that the company will be featured in an article in the “Cell Cycle,” a journal focused on the molecular aspects of cancer research, as a leading example of the emergence of life science entrepreneurship in Eastern Europe. The article will appear in the September 15, 2011, (Volume 10, Issue 18) edition of the journal and is currently available on line at http://www.es.landesbioscience.com/journals/cc/Lamb-CC10-18.pdf

Noting that the company has brought together the founding Hungarian scientist with a world-class team to commercialize the company’s novel technology, author Katrina Lamb writes: “With an experienced, professional management team and board of renowned expert advisors from life sciences centers of excellence around the world, ImmunoGenes would not be out of place in Silicon Valley, Tel Aviv or other hotbeds of entrepreneurial activity.”

“We are delighted to see the excellent work of ImmunoGenes recognized as a leading example of Eastern European entrepreneurship,” said Lee Schalop, Chief Operating Advisor and Head of Business Development for ImmunoGenes, “and we are pleased to be included along with companies like BIA Separations, a leader in its field.”

“It is rewarding for us to see entrepreneurial activity of the quality and substance as reflected in the work of ImmunoGenes from the Eastern European region” said Stephen M. Goodman, partner in the Business and Finance Practice of Morgan Lewis & Bockius LLP, and strategic counsel to startups in the technology and life sciences sectors. Mr. Goodman is also the longest-tenured member of the advisory board for the University of Pennsylvania's Wharton Entrepreneurship Program and teaches "Legal Aspects of Entrepreneurship" at the University of Pennsylvania's School of Law.

Back to Top

July 24, 2011

Budapest, Hungary, and Zug, Switzerland (July 24, 2011) – ImmunoGenes AG announced today that a comprehensive review article on the company’s proprietary FcRn technology is in press in the Journal Mabs, entitled “Recent advances using FcRn overexpression in transgenic animals to overcome impediments of standard antibody technologies to improve the generation of specific antibodies”, Volume 3, Issue 5 September/October 2011 authored by Imre Kacskovics, Judit Cervenak, Anna Erdei, Richard A. Goldsby and John E. Butler.

Effects and mechanisms of neonatal Fc receptor (FcRn) overexpression leading to significantly improved humoral immune responses are summarized. These include: (1) improved IgG protection; (2) augmented antigen-specific humoral immune response with larger numbers of antigen specific B cells, thus offering a wider spectrum of clones; (3) generation of antibodies against weakly immunogenic antigens; (4) significant improvements in the number, and substantial developments in the diversity, of hybridomas.

“We are delighted with the appreciation of our technology by a broad audience of researchers and corporate collaborators. The value of having a remedy to address difficult antigens and/or creating a richer choice of monoclonal antibodies as product candidates introduces an obvious advantage in early stages of development and meaningfully enhances overall likelihood of success,” said Imre Kacskovics, CEO and Vice Chairman of Immunogenes AG and added “ we are committed to work closely with interested parties to make full use of this enabling technology in the context of our Customized Antibody Solution program, further specified on our website “.

Back to Top

July 6, 2011

Budapest, Hungary, and Zug, Switzerland (July 6, 2011) – ImmunoGenes AG announced today increased roles for Lee Schalop and Tonio Barlage in their capacities as consultants to ImmunoGenes. Lee Schalop, MD, has been named Chief Operating Advisor and Tonio Barlage has been named as the Chief Financial Advisor of the company.

Dr. Schalop, operating from his office in NYC, is a Partner at PolyTechnos Venture Partners, a European Venture Capital firm with global presence and a track record of building world-class healthcare companies. He has served as the company’s Head of Business Development and member of the company’s Board of Directors since shortly after the company’s founding.

“Lee has been instrumental in the growth of ImmunoGenes,” said Imre Kacskovics, the CEO of Immunogenes. “Lee’s high level strategic contributions combined with his operational excellence in the execution of our ambitious vision for the ImmunoGenes’ technology platform has made him an integral part of our leadership team. All of us at ImmunoGenes are pleased that Lee will be stepping up his efforts on behalf of the company as we enter into the next important phase in creating value for our shareholders.”

Dr Barlage joined the Board of Directors of ImmunoGenes in 2009 in the context with the Series-A financing round led by Polytechnos. At Polytechnos, Tonio is a Managing Partner since 2003 and serves as a Board member in for the following portfolio companies: Nanotron; Innolume; Panoratio and Framepool. Previously he served as President, COO, and CFO of Sauer, which he took public in 1998 (NYSE: SHS) and which merged with Danfoss Mobile Hydraulics in 2000, creating a company with an international presence and a market capitalization of more than $1 billion. Until 1986, he was manager in the audit division at Arthur Andersen in Düsseldorf, Germany. Tonio received his graduate degree in electrical engineering and his Ph.D. in business administration from the Technical University of Berlin. He also is a Certified Public Accountant and a Certified Tax Adviser.

“It is a great privilege to have Tonio join us in the leadership team of ImmunoGenes and to allow us to benefit from his world-class expertise in all financial aspects of growing our company in this next phase. We have made major progress in developing our technology platform, and we have consolidated these major advances throughout all major corporate functions by expanding the capability map of the organization and adding to the leadership expertise. With Tonio in finance and Lee in operations the company has prepared itself for the major tasks along our value inflection curve,” Beatrice Tschanz Kramel, member of board of directors at ImmunoGenes, added.

Back to Top

May 10, 2011

Budapest, Hungary, and Zug, Switzerland (May 10, 2011) – ImmunoGenes is expanding its Specialty Customer Business under the name of “Customized Antibody Solutions” (CAS).

ImmunoGenes’ Customized Antibody Solutions (CAS) will offer the opportunity to produce antibodies for specialty customers using its proprietary FcRn technology platform. This high end segment will focus on the production of monoclonal antibodies (mAbs) against antigens with weak immune response.

ImmunoGenes has demonstrated and published the benefits of the FcRn technology in several highly visible and peer-reviewed journals: J Immunol 186, 959-968.; Immunology Lett. 137(1-2):62-9. and MAbs. 2011 Mar 1;3(2):173-80.

Please contact ImmunoGenes at antibody@immunogenes.com to obtain a quote.

Back to Top

March 21, 2011

Budapest, Hungary, and Zug, Switzerland (March 21, 2011) – ImmunoGenes AG announced today that the company has been selected to present its technology at the New York Biotechnology Association 20th Annual Meeting on April 6-7 at the Marriott Marquis Hotel in NYC.


Lee Schalop, the company’s Head of Business Development, will present an overview of the Company's business strategy and details on several new findings from its proprietary platform technology to improve antibody generation and production using FcRn-overexpressing animals on Thursday, April 7 at 9:00 AM. The company is also available for one-on-one meetings at the Annual Meeting by contacting Lee Schalop at schalop@immunogenes.com

“We are particularly excited to be presenting at this year’s New York Biotechnology Association Annual Meeting,” said Imre Kacskovics, the CEO of ImmunoGenes, “given the this year’s theme ‘The Cures Starts Here Because the Science Starts Here’. Our company’s proprietary technology that allows for an improved immune response will lead to important advances in critical drugs and diagnostics, and we are proud to be part of a meeting focused on these efforts.”

Back to Top


March 2, 2011

Budapest, Hungary, and Zug, Switzerland (March 2, 2011) – ImmunoGenes AG announced today that the company has been selected to present on the Next Generation track at Bio-Europe Spring in Milan. ImmunoGenes is honored to be part of the Next Generation track, which “features a selected group of young innovative start-up companies from around the world.”

Imre Kacskovics, the company’s CEO, will present overview of the Company's business strategy and details on several new findings of its proprietary platform technology to improve antibody generation and production using FcRn-overexpressing animals on Tuesday, March 15 at 4:40 PM. The company is also available for one-on-one meetings at the Bio-Europe Spring conference through the conference partnering system or by contacting Lee Schalop, Head of Business Development, at schalop@immunogenes.com

Back to Top

January 4, 2011

Budapest, Hungary, and Zug, Switzerland (January 4, 2011) – ImmunoGenes announces the publication of several new findings on its proprietary platform technology to improve antibody generation and production using FcRn-overexpressing animals.

The first new article, which appeared in “The Journal of Immunology” (Cervenak et al.: Neonatal FcR overexpression boosts humoral immune response in transgenic mice. J Immunol 2010 Dec 8. [Epub ahead of print]), indicates that immunization of the company’s transgenic mice with T-dependent antigens results in a multifold increase of the antigen-specific IgG in serum and that the affinity of these antibodies was at least as good as the wild type controls. FcRn overexpression was shown to extend the IgG half-life, dramatically enhancing the expansion of antigen-specific B cells and plasma cells, as well as antigen-IgG phagocytosis by neutrophils, indicating a greatly augmented humoral immune response. Consequently, the enhanced immune response resulting from the FcRn overexpression was associated with a substantial increase in the number of spleen-derived dendritic cells and granulocytes.

Another article is in press in the Journal “mAbs” (Vegh et al.: FcRn overexpression results in potent humoral response against weakly immunogenic antigen), and describes the ability of the FcRn overexpressing system to react to “difficult” antigens. In this experiment, the FcRn-overexpressing animals produced a robust immune response against a conserved influenza hemagglutinin peptide whereas wild-type mice showed only a de minimis amount of antibody against the epitope.

ImmunoGenes will publish shortly additional reports describing the function of increased levels of FcRn in transgenic animals further expanding the company’s novel observations of boosted immune reactions in these animals. These effects include augmented antigen presentation by dendritic cells and increased number of antigen specific hybridomas without any sign of autoimmunity.

ImmunoGenes believes that this additional information, taken together with the information already published by the company, ascribes a capability to its proprietary FcRn tg technology to overcome the handicap of animal immune systems in recognizing “evasive” antigens.

ImmunoGenes is encouraged by these data as a confirmation of its founding vision to enhance the capability of well-established animal systems in the fields of monoclonal and polyclonal antibodies and elevate their immune response to a previously unachievable level.

"It was not foreseeable that the overexpression of the bovine FcRn would have such a meaningful effect on the humoral immune response. And we have now begun to understand how effective this platform technology is on several levels providing a much enriched resource for polyclonal and monoclonal antibody applications," said Ronald Landes, Founder and CEO of Landes BioScience, Austin, Tx, and one of the first investors in ImmunoGenes.

ImmunoGenes’ management is present at the 2011 JPM Health Care Conference (San Francisco, 10-13 Jan, 2011) and is available for meetings for interested parties under kacskovics@immunogenes.com.

Back to Top